FGF2 and myeloid leukemia: This can be through increased transcription of anti-angiogenic factors, including the ISGs IRF7 and PML. Alternatively, Type I IFNs can reduce production of pro-angiogenic factors, including basic fibroblast growth factor (bFGF), a factor increased in myeloid leukaemia (52, 53).